Palmitoylethanolamide (PEA) to Improve Pain and Cognitive Function: A Comprehensive Review

Palmitoylethanolamide (PEA)

A Comprehensive Review of Mechanisms, Clinical Evidence, and Practical Applications

January 2026​

Abstract​

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine family with extensively documented anti-inflammatory, analgesic, immunomodulatory, and neuroprotective effects. Synthesized on demand within the lipid bilayer in response to cellular stress, PEA acts through multiple molecular targets including PPAR-α activation, indirect modulation of the endocannabinoid system via the entourage effect, and stabilization of mast cells and microglia. Clinical evidence from multiple meta-analyses demonstrates significant efficacy in chronic and neuropathic pain conditions with an exceptional safety profile and no documented drug-drug interactions. This review examines PEA's mechanisms of action, clinical applications, optimal formulations, dosing considerations, and practical guidance for supplementation.

Introduction​

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has garnered significant research interest since its initial discovery in the 1950s. Originally identified in lipid fractions of egg yolk and subsequently found in a variety of foods including peanuts, soybeans, and meat, PEA represents the body's natural response to inflammation and cellular stress [1,2].

The therapeutic potential of PEA was first recognized in Czechoslovakia, where the drug manufacturer Spofa introduced Impulsin—a tablet formulation of PEA—in 1970 for the treatment and prophylaxis of influenza and respiratory infections [3]. In Spain, Almirall subsequently introduced Palmidrol in 1976 for similar indications. Despite this early clinical use, research interest in PEA intensified dramatically in the 1990s following the work of Nobel laureate Rita Levi-Montalcini, who described the relationship between PEA and the endocannabinoid anandamide, demonstrating the expression of mast cell receptors sensitive to both molecules [4].

Today, PEA is recognized as an endocannabinoid-like lipid mediator with pleiotropic effects spanning anti-inflammatory, analgesic, anticonvulsant, antimicrobial, antipyretic, antiepileptic, immunomodulatory, and neuroprotective activities [5]. This comprehensive review examines the current understanding of PEA's mechanisms of action, evaluates the clinical evidence supporting its use, and provides practical guidance for supplementation.

Mechanisms of Action​

PEA exerts its biological effects through multiple molecular targets and signaling pathways, which accounts for its broad therapeutic profile. Unlike classical endocannabinoids, PEA lacks significant affinity for cannabinoid receptors CB1 and CB2, leading researchers to explore alternative mechanisms [6].

PPAR-α Activation​

The peroxisome proliferator-activated receptor alpha (PPAR-α) serves as the primary molecular target mediating PEA's neuroprotective, anti-neuroinflammatory, and analgesic effects [7]. PPAR-α is a nuclear receptor that functions as a master switch for genes activating inflammatory cascades. Upon activation by PEA, PPAR-α initiates anti-inflammatory mechanisms including downregulation of NF-κB signaling, reduction of pro-inflammatory cytokine production, and modulation of immune cell responses [8].

Studies using PPAR-α knockout mice have confirmed the essential role of this receptor in mediating PEA's therapeutic effects. In models of Alzheimer's disease, PEA administration reduced behavioral impairments and protected against amyloid-β-induced memory deficits, but these effects were abolished in PPAR-α-deficient animals [9].

The Entourage Effect​

Beyond its direct effects, PEA modulates the endocannabinoid system through what researchers term the "entourage effect." PEA inhibits fatty acid amide hydrolase (FAAH), the enzyme responsible for degrading the endocannabinoid anandamide [10]. By reducing anandamide degradation, PEA effectively increases the levels and duration of action of this endogenous cannabinoid, allowing it to exert its own analgesic and anti-inflammatory effects via CB1 and CB2 receptors [11].

This indirect mechanism contributes to PEA's therapeutic effects while avoiding the psychoactive effects associated with direct cannabinoid receptor agonists like THC. The entourage effect also helps explain why PEA and anandamide appear to have synergistic effects in models of pain and analgesia [12].

GPR55 and GPR119 Activation​

PEA also demonstrates affinity for the orphan G protein-coupled receptors GPR55 (sometimes referred to as the "third cannabinoid receptor") and GPR119 [13]. Activation of these receptors may contribute to PEA's immunomodulatory effects and its influence on energy metabolism. The multi-target nature of PEA's activity helps explain its efficacy across diverse pathological conditions.

Mast Cell and Microglial Modulation​

A distinctive feature of PEA's mechanism of action is its ability to down-regulate hyperactive mast cells and microglia. PEA inhibits the release of both preformed and newly synthesized mast cell mediators, including histamine and TNF-alpha [14]. Additionally, PEA reduces the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and prevents the nuclear translocation of NF-κB [15].

In the central nervous system, PEA's modulation of microglial activity is particularly relevant for neurodegenerative and neuroinflammatory conditions. Activated microglia contribute to secondary neuronal damage in many CNS disorders, and PEA's ability to reduce microglial activation represents a key neuroprotective mechanism [16].

Clinical Evidence​

Chronic Pain​

The strongest clinical evidence for PEA supports its use in chronic pain management. A systematic review and meta-analysis examining double-blind randomized controlled trials found that PEA significantly reduced pain scores relative to comparators, with a standard mean difference of 1.68 (95% CI: 1.05-2.31, p = 0.00001) [17]. Importantly, several studies reported additional benefits for quality of life and functional status, while no major side effects were attributed to PEA in any study.

A 2017 meta-analysis including 10 randomized clinical trials with 786 patients receiving PEA demonstrated that PEA was associated with significantly greater pain reduction compared to inactive control conditions, with a weighted mean difference on a 10-point scale of 2.03 (95% CI: 1.19-2.87) [18]. Notably, the use of placebo control, presence of blinding, allowance for concomitant treatments, and duration or dose of PEA treatment did not affect the measured efficacy.

Neuropathic Pain​

PEA has demonstrated particular efficacy in neuropathic pain conditions, where conventional treatments often provide inadequate relief. Clinical experience with over 1,000 patients suffering from neuropathic pain has shown that PEA, either as monotherapy or combined with standard analgesics, can reduce pain by 40-80% compared to baseline scores [19]. Combinations with tramadol, pregabalin, gabapentin, and duloxetine have never resulted in discomfort or adverse interactions.

Specific conditions where PEA has shown benefit include peripheral diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, postherpetic neuralgia, and neuropathic pain associated with multiple sclerosis [20]. The compound appears to have both analgesic and nerve-protective effects, potentially addressing the underlying pathophysiology rather than simply masking symptoms.

Osteoarthritis​

Clinical trials have demonstrated that oral PEA supplementation reduces pain and improves function in patients with knee osteoarthritis [21]. A double-blind randomized placebo-controlled study assessing safety, tolerability, and efficacy found significant improvements in both pain scores and functional assessments compared to placebo.

Neuroprotection and Brain Health​

Emerging evidence supports PEA's neuroprotective potential in neurodegenerative conditions. In experimental models of Alzheimer's disease, PEA has demonstrated the ability to counteract amyloid-β-induced astrocyte activation and improve neuronal survival [22]. The compound has also shown promise in models of Parkinson's disease, multiple sclerosis, and traumatic brain injury.

A combination formulation of ultramicronized PEA with the antioxidant flavonoid luteolin (co-ultraPEALut) has been studied for post-COVID-19 olfactory impairment in a multi-center double-blind randomized placebo-controlled clinical trial, demonstrating the continued research interest in PEA's neurological applications [23].

Formulation Considerations​

PEA's lipophilic nature and poor water solubility present significant bioavailability challenges for oral supplementation. The compound's large particle size in its native state limits its dissolution rate and absorption when taken orally [24]. These pharmacokinetic limitations have been addressed through advanced formulation technologies.

Particle Size and Bioavailability​

Three primary formulations of PEA are commercially available, distinguished by particle size:

Naïve/Non-micronized PEA: 100-2,000 μm particles

Micronized PEA (PEA-m): 2-10 μm particles

Ultramicronized PEA (PEA-um): 0.8-6 μm particles

Comparative studies have clearly demonstrated the superiority of micronized and ultramicronized formulations. In a rat model of inflammatory pain, carrageenan-induced paw edema and thermal hyperalgesia were markedly and significantly reduced by oral treatment with micronized and ultramicronized PEA at each time point compared to non-micronized PEA. However, when administered by intraperitoneal injection (bypassing oral absorption), all formulations proved equally effective [25]. This finding confirms that the differences in efficacy relate specifically to oral bioavailability rather than intrinsic activity.

Recommendation: For oral supplementation, micronized or ultramicronized PEA formulations are strongly preferred and should be considered essential for optimal therapeutic outcomes.

Dosing Guidelines​

Clinical trials have most commonly employed PEA doses ranging from 300-1200 mg daily, administered over periods of 2-12 weeks [26]. The optimal dosing strategy depends on the condition being treated and individual response.

Recommended Protocol​

Loading Phase: 600 mg twice daily (1200 mg/day total) for the first 2-4 weeks

Maintenance Phase: 600 mg once or twice daily, adjusted based on response

Maximum Studied Dose: Up to 2400 mg/day; PEA has been proven safe in adults at doses up to 50-100 mg/kg body weight [27]

Timing and Administration​

PEA should be taken with food containing fat to enhance absorption. Due to its lipophilic nature, co-administration with fatty foods or other lipid supplements such as fish oil can improve dissolution and bioavailability. Plasma levels of PEA reach peak concentration approximately 15 minutes after oral administration and return to baseline values within about two hours, suggesting that divided dosing throughout the day may provide more consistent tissue levels [28].

Onset of Action​

Unlike conventional analgesics, PEA's effects are often cumulative rather than immediate. While some studies have reported significant pain reduction after just 10-14 days, most clinical trials did not observe significant benefits until approximately four weeks of treatment [29]. Patients should be counseled to continue supplementation for at least 4-8 weeks before assessing efficacy. The delayed onset reflects PEA's mechanism of action, which involves modulating cellular processes and gene expression rather than simply blocking pain signals.

Safety Profile​

PEA demonstrates an exceptional safety profile, which is likely related to its status as an endogenous compound that is naturally produced by the body and present in common foods.

Clinical Safety Data​

A 2016 comprehensive safety assessment examining sixteen clinical trials, six case reports/pilot studies, and a meta-analysis concluded that for treatment periods up to 49 days, clinical data argued against serious adverse drug reactions at an incidence of 1/200 or greater [30]. A pooled meta-analysis involving twelve studies found that no serious adverse events were registered or reported.

The rare mild side effects that have been reported include gastrointestinal discomfort, headache, dizziness, and very rarely nausea, palpitations, or drowsiness. These effects are generally transient and often resolve with continued use or by starting with a lower dose and gradually increasing [31].

Special Populations​

There are no known contraindications for PEA, and importantly, patients with reduced kidney and liver function can be treated with PEA because its metabolism is localized and cellular, independent of hepatic and renal function [32]. This characteristic makes PEA particularly suitable for elderly patients who may have compromised organ function and are already taking multiple medications.

Regarding pregnancy and breastfeeding, there is insufficient reliable information to establish safety during these periods. The conservative recommendation is to avoid use during pregnancy and lactation until more data become available [33].

Drug Interactions​

To date, no drug-drug interactions have been documented with PEA [34]. This remarkable absence of interactions is likely due to PEA's status as an endogenous lipid that is produced on demand in cellular membranes and easily metabolized into components that are recycled within those membranes.

PEA has been safely combined with numerous medication classes including:

• Anticonvulsants (pregabalin, gabapentin)

• Opioid analgesics (tramadol and others)

• Antidepressants (duloxetine, citalopram, amitriptyline)

• Non-steroidal anti-inflammatory drugs

• Other supplements (alpha-lipoic acid, fish oil)

Importantly, PEA not only can be safely combined with conventional analgesics but appears to enhance their efficacy. Clinical experience suggests that adding PEA (1200 mg/day) to existing pain regimens allows for subsequent tapering of opioids or other analgesics without loss of efficacy, resulting in reduced adverse events and improved compliance [35].

Tolerance and Dependence​

Unlike opioid analgesics or substances that act directly on cannabinoid receptors, PEA does not appear to cause tolerance or dependence. Its mechanisms of action—primarily PPAR-α activation and indirect endocannabinoid modulation—are less prone to the rapid receptor downregulation seen with direct agonists [36]. This characteristic makes PEA suitable for long-term use in chronic conditions.

Synergistic Combinations​

Several combination formulations have been developed to enhance PEA's therapeutic potential:

PEA + Luteolin: A co-ultramicronized formulation in a 10:1 ratio has demonstrated enhanced neuroprotective effects in experimental models of neurodegeneration and has been studied for post-COVID olfactory impairment [37].

PEA + Polydatin: This combination has been studied for endometriosis-related pelvic pain and irritable bowel syndrome, showing synergistic analgesic properties [38].

PEA + XXX: As PEA activates PPAR-α while also working through the endocannabinoid system, it targets similar pathways as cannabidiol (XXX). With proven efficacy and an excellent safety profile, PEA represents both an alternative to and potential combination partner with XXX for various inflammatory and pain conditions [39].

Summary of Therapeutic Applications​

Strong Evidence: Chronic pain, neuropathic pain, osteoarthritis, sciatic pain, carpal tunnel syndrome

Moderate Evidence: Fibromyalgia, irritable bowel syndrome, endometriosis-related pain, temporomandibular joint disorders, depression (as adjunct therapy)

Emerging/Preclinical: Neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis), post-COVID symptoms, glaucoma, amyotrophic lateral sclerosis, autism spectrum disorders

Conclusions​

Palmitoylethanolamide represents a unique therapeutic compound that leverages the body's endogenous mechanisms for managing inflammation and pain. Its multi-target mechanism of action—encompassing PPAR-α activation, indirect endocannabinoid modulation, and stabilization of mast cells and microglia—provides a strong rationale for its efficacy across diverse conditions.

The clinical evidence, particularly from meta-analyses of randomized controlled trials, consistently demonstrates PEA's ability to reduce pain and improve function in chronic pain conditions. Its exceptional safety profile—with no documented drug interactions, no tolerance development, and suitability for patients with hepatic or renal impairment—distinguishes it from conventional analgesics and anti-inflammatory agents.

For optimal therapeutic outcomes, supplementation with micronized or ultramicronized PEA formulations is essential. A typical regimen of 600 mg twice daily, taken with food, for at least 4-8 weeks allows adequate time for the compound's cumulative effects to manifest. PEA can be used as monotherapy or safely combined with existing medications, potentially allowing for dose reduction of conventional analgesics.

As research continues to elucidate PEA's neuroprotective and immunomodulatory properties, its therapeutic applications are likely to expand beyond pain management into neurodegenerative diseases and other conditions characterized by chronic inflammation.

References​

1. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349-1365.

2. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-942.

3. Masek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol. 1974;7(6):415-419.

4. Facci L, Dal Toso R, Romanello S, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 1995;92(8):3376-3380.

5. Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016;62:107-128.

6. Sugiura T, Kondo S, Kishimoto S, et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. J Biol Chem. 2000;275(1):605-612.

7. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19.

8. Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol Res. 2014;86:32-41.

9. D'Agostino G, Russo R, Avagliano C, et al. Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology. 2012;37(7):1784-1792.

10. Di Marzo V, Melck D, Orlando P, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001;358(Pt 1):249-255.

11. Ho WS, Barrett DA, Bhondall MD. Ligand specificity of monoacylglycerol lipase and hormone-sensitive lipase. J Lipid Res. 2008;49(6):1133-1140.

12. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394(6690):277-281.

13. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092-1101.

14. De Filippis D, D'Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol. 2008;20(Suppl 1):20-25.

15. Costa B, Conti S, Giagnoni G, Bhondall M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002;137(4):413-420.

16. Skaper SD, Facci L, Barbierato M, et al. N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol. 2015;52(2):970-991.

17. Pickering EE, Steels EL, Steadman KJ. A systematic review and meta-analysis of palmitoylethanolamide in the treatment of chronic pain. J Pain. 2023;24(8):1374-1392.

18. Paladini A, Fusco M, Cenacchi T, et al. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11-24.

19. Keppel Hesselink JM, Hekker TAM. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-442.

20. Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22(2):79-94.

21. Steels E, Venkatesh R, Steels E, et al. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019;27(3):475-485.

22. Scuderi C, Esposito G, Blasio A, et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med. 2011;15(12):2664-2674.

23. Di Stadio A, D'Ascanio L, Vaira LA, et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial. Curr Neuropharmacol. 2022;20(10):2001-2012.

24. Petrosino S, Moriello AS. Palmitoylethanolamide: A nutritional approach to keep neuroinflammation within physiological boundaries—A systematic review. Int J Mol Sci. 2020;21(24):9526.

25. Impellizzeri D, Bruschetta G, Cordaro M, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136.

26. Artukoglu BB, Beyer C, Zuloff-Shani A, et al. Efficacy of palmitoylethanolamide for pain: A meta-analysis. Pain Physician. 2017;20(5):353-362.

27. Keppel Hesselink JM. Chronic pain and the use of palmitoylethanolamide: an update. Int J Orthop Traumatol. 2018;2(1):1-3.

28. Petrosino S, Cordaro M, Verde R, et al. Oral ultramicronized palmitoylethanolamide: Plasma and tissue levels and spinal anti-hyperalgesic effect. Front Pharmacol. 2018;9:249.

29. Tartaglia E, Armentaro M, Giugliano A, et al. Chronic pain: an update on the use of palmitoylethanolamide. J Pain Res. 2022;15:1881-1896.

30. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-942.

31. Resolve Pain. Patient information: Palmitoylethinolamide (PEA). Resolve Pain Education Resources. 2024.

32. Accurate Clinic. Accurate Education - Palmitoylethanolamide (PEA). Clinical Education Resources. 2017.

33. WebMD. Palmitoylethanolamide (PEA): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews. WebMD Vitamins & Supplements. 2024.

34. Keppel Hesselink JM. Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical. J Pain Res. 2013;6:625-634.

35. Gatti A, Lazzari M, Gianfelice V, et al. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121-1130.

36. Noomind. Palmitoylethanolamide (PEA): Mechanisms for Pain, Inflammation, and Neuroprotection. Noomind Scientific Reviews. 2024.

37. Paterniti I, Cordaro M, Campolo M, et al. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets. 2014;13(9):1530-1541.

38. Cremon C, Stanghellini V, Barbaro MR, et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017;45(7):909-922.

39. Allied Academies. Palmitoylethanolamide: An organic and cannabimimetic compound with pleiotrophic effects - A review. J Clin Cell Immunol. 2022;13(4):20206.

Disclaimer: This article is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement regimen, especially if you have existing health conditions or are taking medications.

 

Has anyone tried this supplement?

 

Thread 'Palmitoylethanolamide (PEA) for pain'

Mar 19, 2024

Anyone hear of this or tried it? Obviously something is missing with me on TRT. Pregnenolone and DHEA help some but don't exactly hit the spot and have differnet effects for me that aren't just right. So somehow I stumbled upon this and its effect on nuerosteroids. People have mentioned that it helps their body aches, mental health, and libido. A few andecdotes hypothesize that this could be the missing link for the hormonal cascade that TRT inhibits. A guy on gootube (madman shoutout) states that this reversed his Post Finasteride Syndrome by getting his 5AR back on track and...

• DixieWrecked
• palmitoylethanolamide
• Replies: 11
• Forum: When TRT Is Not Enough (ED, Libido, & More)

• 

 

Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical​

 

Has anyone tried this supplement?

I did once and didn't really get much from it at the time. I'm not sure i trusted the brand i bought though to be honest. I'm thinking of trying it again to see if it helps with my shoulder pain (had x-rays this week showing severe osteoarthritis in both). It's not cheap to buy here in the UK - at least for humans. I've just found a supplier selling it for horses - a 0.5kg bag (micronised) for £39.99.

PEA For Horses | Ultra-Micronised | High Purity

Forageplus Ultra-Micronised PEA for Horses. Over >99% pure Palmitoylethanolamide - Powder Form Easy Feeding - Shop Now!

forageplus.co.uk

I'm tempted to buy that and give it another go. If people buy it for their horses, i'm guessing the quality is going to be good!

 

Heck, I want those benefits! LOL

 

For a 80 Kg man I guess the dose will be (6/500)x80=960 mg ? (close to the 600 mg mentioned in my article)

It says take it with a fatty source by micronized linseed to maximize absorption.

 

Heck, I want those benefits! LOL

View attachment 55005

I'm very close to buying it, due to it being ultra micronized and so much cheaper than anything else i've seen. Just a bit concerned about potential contaminants (maybe heavy metals?) due to it not being human grade. But saying that, i buy supplements through ebay all the while, and i always go by price without checking for any purity certification. I was down a rabbit hole looking into human use of horse supplements earlier, and found discussions about humans using this (Adequan) for joint problems that looked interesting -

Polysulfated glycosaminoglycan - Wikipedia

en.wikipedia.org

 

I ended up buying the ultra-micronised one (for horses) that i mentioned above, and started Wednesday evening with a meal. I'll be taking 1200mg, split 600/600 as per the article Nelson posted, for the first month or so, and update here. I'm mostly hoping it'll help calm down the shoulder pain i get, and also arthritic thumb pain that sometimes flairs up. I've just skimmed over some articles mentioning it might lower LDL cholesterol too, which would be great as mine always comes back high in blood work.

 

I am taking one 600 mg capsule also twice per day with food.

 

Human Studies on PEA and Cognitive Function​

1. Healthy Adults (Memory & BDNF)​

A randomized double-blinded placebo-controlled cross-over trial measured the effects of a 6-week 700 mg/day course of formulated PEA supplementation (Levagen+®) versus placebo in 39 healthy adults. A significant increase in serum BDNF levels was found following PEA supplementation compared with placebo (p = 0.0057, d = 0.62). The cognition test battery demonstrated improved memory with PEA supplementation through better first success and fewer errors. PubMed Central

This was the first study to report a direct beneficial effect of PEA supplementation on memory improvement as well as corresponding increases in circulating neurotrophic marker levels. This suggests that formulated PEA holds promise as an innovative and practical intervention for cognitive health enhancement. PubMed Central


The CANTAB® Paired Associates Learning test was used, which is considered one of the most sensitive means of measuring memory and learning ability and has been used for more than 100 years in human neuropsychopharmacological studies. PubMed Central

---

2. Stroke Patients​

One open-label clinical study in 250 stroke patients reported that treatment with co-ultramicronized PEA (700 mg) + luteolin (70 mg) for 60 days significantly improved cognitive function and muscle spasticity. The average MMSE score over 30 days of treatment increased from 20.2 to 22.7. Alzdiscovery


Patients' independence and mobility in daily living activities showed a significant improvement after 30 and 60 days of treatment. The difference was significant between 30 and 60 days, suggesting continued improvement with time. Alzdiscovery


Caveat: This was an open-label study, and stroke patients typically show spontaneous functional improvement over time.

---

3. Parkinson's Disease​

In a study of 30 PD patients receiving levodopa, ultramicronized PEA (600 mg) was assessed as adjuvant therapy. The MDS-UPDRS questionnaire was used to assess motor and non-motor symptoms before and after PEA addition. PubMed


Um-PEA slowed down disease progression and disability in PD patients, suggesting that um-PEA may be an efficacious adjuvant therapy for PD. PubMed

---

4. Frontotemporal Dementia (FTD)​

A study investigated the cognitive and neurophysiological effects of four weeks of PEALut administration in seventeen patients with FTD. Patients underwent extensive cognitive and behavioral assessment including neuropsychiatric inventory (NPI), MMSE, frontal assessment battery (FAB), and screening for aphasia in neurodegeneration (SAND). MDPI


Surprisingly, the results showed that PEALut can improve frontal lobe function and behavioral disturbances, mainly through the modulation of GABAergic activity and high-frequency cortical oscillations. MDPI

---

5. Mild Cognitive Impairment (MCI)​

One study investigated the efficacy of nine months PEALut high-dose administration in amnestic MCI in a patient. At the nine-months follow-up, the neuropsychological evaluation was almost normal, and the SPECT hypometabolism was normalized. MDPI


A retrospective observational study of MCI subjects receiving PEALut showed significant amelioration in behavioral symptoms measured by NPI scores compared to dietary supplements or no treatment.

---

6. Meta-Analysis Results​

Colizzi et al. (2022), in their systematic review and preliminary meta-analysis, demonstrated that PEA significantly improves cognitive function, as evidenced by enhanced Mini-Mental State Examination (MMSE) scores of 3.80 points (95% CI: −0.16 to 7.75), indicating a trend toward cognitive enhancement, and positively affects executive function, working memory, language deficits, and daily living activities. PubMed Central

---

7. Sleep & Next-Day Cognition​

300 mg/day of Levagen+® over 8 weeks significantly reduced sleep onset latency and improved next-day cognition. Frontiers

---

Proposed Mechanisms for Cognitive Effects​

The cognitive benefits are thought to relate to several mechanisms:

1. BDNF Enhancement: PEA increases brain-derived neurotrophic factor, which is critical for synaptic plasticity, learning, and memory
2. Anti-Neuroinflammation: By reducing microglial activation and pro-inflammatory cytokines, PEA may protect against neuroinflammation-induced cognitive impairment
3. GABAergic Modulation: In FTD studies, PEA appeared to work through modulation of GABAergic activity
4. Neuroprotection: Protection against excitotoxicity and oxidative damage in vulnerable brain regions

---

Key Limitations​

• Most cognitive studies are small sample sizes or case reports
• Many studies are open-label without placebo controls
• The stroke study confounds are significant (spontaneous recovery)
• No large-scale RCTs specifically powered for cognitive endpoints in healthy aging or dementia prevention
• Most positive data comes from PEA + luteolin combinations rather than PEA alone

---

Bottom Line​

The human data is promising but preliminary. The strongest evidence comes from the 2024 RCT in healthy adults showing improved memory and increased BDNF. For neurodegenerative conditions, the data is encouraging but based largely on small open-label studies. Neurocognitive disorders represent the group of conditions where the use of PEA seems most supported by research studies, with an overwhelming convergence of evidence toward a therapeutic effect on core cognitive symptoms and underlying neurobiological underpinnings. Frontiers

 

Clinical Development Protocol: Palmitoylethanolamide (PEA) for Neurocognitive Recovery and Neuroprotection​

1. Scientific Rationale and Preclinical Foundation​

In the current landscape of neurodegenerative therapeutics, neuroinflammation has transitioned from a secondary symptom to a primary strategic target. While traditional acetylcholinesterase (AChE) inhibitors provide transient symptomatic relief by augmenting cholinergic tone, they fail to address the underlying inflammatory cascade that drives neuronal death. Palmitoylethanolamide (PEA) represents a foundational shift in this paradigm. As an endogenous lipid mediator, PEA targets the peroxisome proliferator-activated receptor-alpha (PPAR-\alpha) pathway to restore homeostatic balance. This protocol views the modulation of the M1-to-M2 microglial phenotype switch not merely as a benefit, but as a mandatory pharmacodynamic prerequisite for disease modification. By shifting microglia from a neurotoxic (M1) to a neuroprotective/pro-resolving (M2) state, we aim to halt the progression of early-stage cognitive disorders.
Preclinical evidence establishes that PEA significantly mitigates \beta-amyloid-induced astrogliosis, reducing the expression of pro-inflammatory markers and lipid peroxidation. Critically, astrocyte vulnerability is exacerbated by the APOE4 genotype, where tau protein aggregates and ApoE4 status converge to trigger astrocyte apoptosis. PEA intervention is strategically designed to blunt this reactive proliferation and stabilize the "connectopathy" observed in these high-risk profiles.

Biological Drivers of Clinical Efficacy​

The efficacy of PEA is underpinned by several synergistic pharmacological mechanisms:

• The "Entourage Effect": PEA facilitates the indirect elevation of anandamide (AEA) by competing for the activity of fatty acid amide hydrolase (FAAH), thereby increasing endocannabinoid tone.
• Indirect Cannabinoid Modulation: While PEA lacks high direct affinity for CB1/CB2 receptors, it enhances their expression and facilitates activation via the entourage effect.
• GPR55 Ligand Activity: PEA acts on the orphan G-protein coupled receptor 55, modulating both excitatory and inhibitory transmission in key regions like the striatum and hippocampus.
• Synaptic Restoration: PEA prevents the desensitization of nicotinic acetylcholine receptors (nAChRs) and mitigates glutamate excitotoxicity, preserving Long-Term Potentiation (LTP).

This scientific foundation justifies a protocol focused on rescuing synaptic machinery before the transition to irreversible neurodegeneration.

2. Clinical Study Objectives and Strategic Hypotheses​

The translation of preclinical "learning and memory" improvements into human clinical efficacy requires a rigorous focus on quantifiable synaptopathy markers. Our strategic objective is to prove that PEA-mediated neuroprotection manifests as significant gains in global executive function and cortical connectivity.

Primary and Secondary Hypotheses​

• Primary Hypothesis: Standardized PEA administration (600–1,200 mg/day) will achieve a target improvement of 3.80 points on the Mini-Mental State Examination (MMSE) in patients with mild-to-moderate impairment, reflecting a clinically significant reversal of cognitive decline.
• Secondary Hypotheses:
  1. Restoration of GABAergic transmission and high-frequency (40 Hz) gamma oscillations.
  2. Reduction of central neuroinflammatory markers, specifically IL-1\beta, IL-6, and TNF-\alpha.
  3. Stabilization of respiratory decline in motor neuron populations.

Target Population vs. Expected Therapeutic Impact​

Target Population	Expected Therapeutic Impact
Ischemic Stroke	Amelioration of neurological status (CNS scale) and daily independence within 30 days.
Alzheimer’s (AD)	Mitigation of early synaptic dysfunction and reduction of hippocampal tau phosphorylation.
FTLD	Reversal of frontal lobe "connectopathy" and high-frequency oscillation deficits.
ALS	Slowing the decline of Forced Vital Capacity (FVC) and protecting nAChR sensitivity.

These objectives focus specifically on the biological window where neuroplasticity remains viable.

3. Patient Cohort Selection and Inclusion Criteria​

Strategic patient stratification is the most critical variable in neuroprotective trials. Evidence confirms that PEA’s effectiveness is maximized in the "prodromal" or "early stage" phases. In late-stage "frank" dementia, microglial phenotypic flexibility is essentially lost, and the PPAR-\alpha mediated response system is exhausted.

Standardized Inclusion Criteria​

Cohort A (Early Neurodegenerative Decline - AD/MCI):

• Diagnosis of mild-to-moderate neurocognitive impairment (MCI or early AD).
• Required Screening: Documentation of APOE4 status to identify patients with increased astrocyte vulnerability.
• MMSE score range of 18–26 at baseline.

Cohort B (Acquired/Secondary Cognitive Impairment):

• Subgroup B1 (Acquired): Post-ischemic stroke (stabilized recovery) or moderate Traumatic Brain Injury (TBI).
• Subgroup B2 (Secondary): Parkinson’s Disease (PD) exhibiting non-motor symptoms (fatigue, sleep disturbances).

Exclusion Justification​

Patients with advanced dementia or late-stage ALS (FVC < 50%) are excluded. The protocol requires preserved microglial plasticity (the ability to undergo the M1-to-M2 switch) to achieve disease-modifying goals.

Clinical Screening Biomarkers (Required)​

1. Endocannabinoid Profiling: Quantitative assessment of peripheral PEA, 2-AG, and AEA levels.
2. Neurophysiological Baseline: Transcranial Magnetic Stimulation (TMS) to establish baseline cortical oscillatory activity.
3. Genomic Stratification: APOE4 genotyping for all AD/MCI participants.

4. Treatment Regimen and Dosage Standardization​

The protocol utilizes a dosage range established for therapeutic saturation (600–1,200 mg/day) while leveraging the high safety profile of an endogenous lipid.

Dosage and Formulation Strategy​

The standardized intervention will utilize:

• Ultramicronized PEA (um-PEA): For superior systemic absorption and blood-brain barrier penetration.
• Composite co-ultraPEALut (PEA 700mg + Luteolin 70mg): Reserved for Cohorts A and B2.

Strategic Advantage (The "So What?"): The addition of Luteolin is essential for its antioxidant synergy and its unique modulation of the gut-microbiota-liver-brain axis. This axis-level intervention enhances hippocampal neurogenesis and insulin sensitivity, providing a multi-system approach to neuroprotection that PEA alone cannot achieve.

Administration Methodology​

• Route: Oral (BID) for chronic management; Sublingual for acute stroke recovery to ensure rapid bioavailability.
• Frequency: Twice Daily (BID) to maintain consistent plasma concentration and provide "on-demand" lipid availability for neural repair.

5. Primary and Secondary Outcome Measures​

A multi-modal assessment approach is required to link behavioral improvements to underlying biochemical and neurophysiological changes.

Primary Outcome Measure​

• MMSE Point Change: A target improvement of 3.80 points over the study duration, as established by the Colizzi et al. meta-analysis.

Secondary Neurophysiological Measures​

• TMS-EEG Assessment:
  1. Restoration of Long-Interval Intracortical Inhibition (LICI) at ISI 100ms.
  2. Increased frontal lobe activity and power in the beta/gamma range (40 Hz), indicating improved synaptic efficacy.

Biochemical and Clinical Endpoints​

• Cytokine Panel: Reduction in IL-1\beta, IL-6, and TNF-\alpha.
• Neurotrophic Support: Measurement of BDNF and GDNF levels in serum/CSF.
• ALS-Specific: Stability in Forced Vital Capacity (FVC) and AChR current desensitization.

6. Safety, Tolerability, and Monitoring​

The strategic value of PEA lies in its "clean" safety profile, which is critical for long-term compliance in elderly populations. As a naturally occurring substance, PEA lacks the toxicological burden of synthetic alternatives.

Safety Data Synthesis​

Human data across Stroke, TBI, PD, and ALS confirm that PEA is well-tolerated with no serious adverse effects. Its lack of interaction with common neurodegenerative medications (e.g., Levodopa, Riluzole) makes it an ideal adjunctive therapy.

Safety and Compliance Monitoring Schedule​

• Bi-Weekly Clinical Interviews: Monitoring for gastrointestinal tolerance and compliance.
• Neurological Scales (Targeted):
  • Stroke Cohort: Canadian Neurological Scale (CNS) assessments.
  • PD Cohort: MDS-UPDRS scale to monitor Non-Motor Aspects of Experiences of Daily Living (nM-EDL), focusing on cognitive fatigue and sleep.
• Vital Signs: Monthly FVC assessment for ALS participants to monitor respiratory stability.

Summary​

This protocol elevates PEA from a nutraceutical to a standardized clinical intervention. By targeting the PPAR-\alpha pathway and the M1-to-M2 microglial switch, we address the root connectopathy of neurodegeneration. This strategy offers a robust, safe, and disease-modifying framework for restoring cognitive health across diverse neurocognitive disorders.

 

Technical Evaluation Report: Palmitoylethanolamide (PEA) Formulation Strategies for Neurocognitive Therapeutics​

1. Strategic Context: The Neuroinflammatory Paradigm in Neurodegeneration​

The pharmaceutical landscape for neurocognitive disorders (NCDs) is undergoing a fundamental strategic pivot. As traditional protein-clearing models for Alzheimer’s and related dementias continue to face clinical hurdles, drug development has shifted toward modulating the neuroinflammatory microenvironment. Palmitoylethanolamide (PEA), an endogenous N-acylethanolamine (NAE) lipid mediator, represents a frontier in this shift. Synthesized "on-demand" from membrane phospholipids in response to cellular stress, PEA functions as a homeostatic regulator. Given the projected global burden of NCDs—reaching 100 million cases by 2050—pharmaceutical interest in PEA is driven by its ability to bolster endogenous repair mechanisms in conditions like Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), and Amyotrophic Lateral Sclerosis (ALS).
According to core source data, PEA serves as a multi-target regulator addressing the following biological underpinnings:

• Astrocyte and Microglial Activation: Restraining reactive gliosis and blunting the transition to pro-inflammatory M1 phenotypes.
• Oxidative Stress: Reducing reactive oxygen species (ROS) production, lipid peroxidation, and protein nitrosylation.
• Synaptic Deficit and Excitotoxicity: Preventing the progressive loss of neural function by regulating aberrant glutamatergic signaling.
• Pro-inflammatory Cytokine Cascades: Inhibiting the synthesis of IL-1\beta, IL-6, and TNF-\alpha.

The therapeutic potential of PEA is contingent upon its complex molecular signaling, moving beyond simple cannabinoid receptor binding to a broader homeostatic synergy.
--------------------------------------------------------------------------------

2. Mechanistic Analysis: The Multi-Target Synergy of PEA​

For a lead formulator, the value of PEA is not found in traditional cannabinoid (CB) receptor affinity, which is notably low. Instead, efficacy is derived from a multi-target approach that integrates nuclear receptor activation with indirect endocannabinoid modulation.

PPAR-\alpha Activation and NF-\kappa B Inhibition​

The primary mechanism for PEA’s neuroprotective action is the activation of the Peroxisome Proliferator-Activated Receptor-alpha (PPAR-\alpha).

• Strategic Impact: PPAR-\alpha activation leads to the inhibition of the NF-\kappa B signaling pathway. This downregulates the synthesis of pro-inflammatory enzymes and markers, effectively halting the chronic inflammatory cycle that characterizes neurodegenerative progression.

GPR55/TRPV1 Modulation and the "Entourage Effect"​

PEA acts as an agonist for the orphan receptor GPR55 and a modulator of TRPV1 channels.

• Strategic Impact: Through the "entourage effect," PEA inhibits the enzyme FAAH, which degrades the endocannabinoid anandamide (AEA). This indirectly increases AEA levels, enhancing cannabinoid-mediated neuroprotection without the adverse effects of direct agonists.

Glutamatergic/GABAergic Rebalancing and Gamma Oscillations​

PEA addresses "synaptopathy" by restoring the balance between excitatory and inhibitory transmission.

• Strategic Impact: PEA inhibits aberrant glutamate release by reducing Ca^{2+} influx, preventing excitotoxic cell death. Crucially, PEA enhances GABAergic transmission by modulating the synthesis of 2-Arachidonoylglycerol (2-AG). This restoration of cortical inhibitory tone is vital for stabilizing high-frequency Gamma Oscillations (40 Hz). Restoring these oscillations is a primary marker for reversing synaptic dysfunction in FTD and AD, as verified by TMS-EEG data.

--------------------------------------------------------------------------------

3. Comparative Evaluation of PEA Formulations​

In neuropharmacology, the formulation is as critical as the molecule. PEA’s lipid nature and poor water solubility necessitate advanced delivery systems to achieve CNS penetration.

Formulation	Targeted Phenotype	Formulator’s Evaluation
Micronized PEA (PEAm)	Aged models; General inflammation.	Basic particle size reduction; shows efficacy in preventing hippocampal cell proliferation loss in aged models.
Ultra-micronized PEA (um-PEA)	Alzheimer’s Disease; Parkinson’s Disease (PD).	Superior learning/memory rescue and reduction of Tau phosphorylation. Critical for restoring mitochondrial bioenergetics in the frontal cortex. Note: Following Brotini (2017), um-PEA at 600mg is the verified clinical choice for PD adjunctive therapy.
Co-ultraPEALut (PEA + Luteolin)	FTD; Stroke; Traumatic Brain Injury (TBI).	Synergistic combination with the flavonoid Luteolin. It promotes hippocampal neurogenesis and significantly increases BDNF/GDNF expression.
PEA-oxazoline (PEA-OXA)	Vascular Dementia (VaD); Chronic Pain.	Effectively reduces neuroinflammation and oxidative stress associated with common carotid artery occlusion models.

Formulation Rationale & Chemical Stability: The Co-ultraPEALut formulation currently represents the gold standard for neurocognitive intervention. From a formulation perspective, the addition of flavones like Luteolin during the ultra-micronization process serves a dual purpose: it provides a synergistic antioxidant effect and stabilizes the PEA molecules, significantly enhancing their pharmacological activity and resistance to degradation.
--------------------------------------------------------------------------------

4. Assessment of Administration Routes and Pharmacokinetics​

Bioavailability remains the primary bottleneck in geriatric populations. Strategic selection of the delivery route is required to navigate compromised metabolic profiles and the blood-brain barrier.

• Sublingual Administration: This route is preferred for stroke and Parkinson’s patients due to the rapid onset of action. By bypassing first-pass metabolism, sublingual PEALut (700mg + 70mg) has demonstrated significant recovery in global executive function and independence in daily living within a 30-day window.
• Oral Administration: Effective for long-term management in FTD, TBI, and ALS. Clinical studies utilize high-dose protocols (up to 1,200mg/day) to maintain therapeutic plasma concentrations over 6–12 months.

The Strategic "Therapeutic Window": Clinical evidence suggests that PEA levels are elevated in the prodromal (early) stages of NCDs as an endogenous compensatory attempt to restore homeostasis. However, this natural defense system fails as the disease enters the "frank" symptomatic stage, at which point endogenous levels fall. Pharmaceutical intervention must target this "window of biological opportunity" early to bolster repair processes before they are overwhelmed by pathology.
--------------------------------------------------------------------------------

5. Clinical Efficacy and Symptom Management across NCDs​

PEA is positioned as a sophisticated adjunctive therapy that addresses the symptomatic and structural markers of NCDs.

• Alzheimer’s (AD): Clinically reduces A\beta expression and Tau hyperphosphorylation; stabilizes mitochondrial function in the frontal cortex.
• Frontotemporal Dementia (FTD): Restores GABAergic transmission and high-frequency oscillations; significantly improves frontal lobe executive functions and behavioral disturbances.
• Amyotrophic Lateral Sclerosis (ALS): Slows the decline of Forced Vital Capacity (FVC). Mechanistically, PEA reduces the desensitization of human e-AChRs subtype (acetylcholine receptors) in muscle membranes, providing a technical basis for its efficacy in maintaining respiratory function.
• Stroke & TBI: Enhances the recovery of executive function and daily mobility; promotes neurogenesis via increased BDNF.

Statistical Caveat on Meta-Analysis Data: While meta-analyses report a 3.80-point pooled change in MMSE scores, pharmaceutical developers must interpret this with professional caution. The 95% Confidence Interval (-0.16 to 7.75) crosses zero, and the heterogeneity observed in these preliminary studies is exceptionally high (I^{2} = 98.40%). While promising, this necessitates larger, more rigorous Phase III trials to confirm standalone clinical significance.
--------------------------------------------------------------------------------

6. Therapeutic Viability: Safety, Tolerability, and Patient Factors​

The viability of PEA is anchored in its exceptional safety profile, which is paramount for the long-term treatment of elderly patients with multiple comorbidities.

• Safety Profile: PEA is remarkably well-tolerated. Across all evaluated human studies, no serious adverse events were reported, even at 1,200 mg/day for 12 months.
• Demographic Sensitivity: Efficacy is stable across varying age and education levels. Risk of bias analysis confirms that demographics do not significantly diminish the treatment effect.
• Strategic Adjunctive Use: PEA has shown no adverse interactions when combined with Levodopa (PD) or Riluzole (ALS). In most cases, PEA acts as a potentiator, improving the clinical outcomes of these standard pharmaceutical agents.

--------------------------------------------------------------------------------

7. Final Assessment: Recommended Formulation Strategy​

For pharmaceutical developers, the objective is to leverage the "endogenous compensatory window" through superior chemical delivery.
Ranking of Formulation Efficacy:

1. Co-ultraPEALut: Highest potential for global repair, neurogenesis, and molecular stability.
2. Ultra-micronized PEA (um-PEA): Primary choice for mitochondrial stabilization and Tau pathology in early AD.
3. PEA-OXA: Specialized for vascular-related neurodegeneration.

High-Level Strategic Recommendations:

1. Mandatory Formulation Choice: Future developments should focus exclusively on the co-ultramicronization of PEA with flavones. This process is essential not only for particle size reduction but for the chemical stabilization of the molecule to ensure consistent CNS delivery.
2. Dosing Imperative: Standardize a therapeutic range of 600–1,200 mg/day. Lower dosages are statistically less likely to achieve the required rebalancing of glutamatergic transmission in symptomatic populations.
3. Target Stage Strategic Imperative: Clinical recruitment must prioritize prodromal and early-stage patients. The strategic value of PEA is its disease-modifying potential during the endogenous compensatory phase; once the "frank" stage of decline is reached, the biological window of opportunity for neural rescue is significantly diminished.

Conclusion: Palmitoylethanolamide is a robust, multi-modal candidate for the next generation of neurocognitive care. Its ability to combat "synaptopathy" by restoring inhibitory tone and gamma oscillations positions it as a valid disease-modifying agent in the evolving landscape of neurodegenerative therapeutics.

 

Biobehavioral and Synaptic Effects of Palmitoylethanolamide (PEA) in Neurocognitive Disorders
Based on 3 sources

Study Reference	Model / Population	Condition Studied	PEA Formulation & Dosage	Primary Mechanism of Action	Cognitive / Synaptic Outcome	Inflammatory / Neuroprotective Effect
D'Agostino et al. (31)	Animal — AD mice (WT & PPAR-α −/−)	Alzheimer's Disease (Aβ25-35-induced)	PEA 3, 10, or 30 mg/kg sc	PPAR-α activation; reduction of lipid peroxidation and nitrosylation	Restores learning and memory impairment (Y-Maze, Morris Water Maze)	Neuroprotective; reduces caspase-3 activation and oxidative stress
Scuderi et al. (34)	Animal — Aβ-exposed rats	Alzheimer's Disease (Aβ-induced)	PEA 10 mg/kg ip daily × 7 days	PPAR-α activation; modulation of amyloidogenic and Wnt pathways	Prevents memory impairment (MWM); improves neuronal integrity	Counteracts reactive gliosis; anti-inflammatory and neuroprotective
Assogna et al. (27)	Human — Frontotemporal Dementia patients	Frontotemporal Dementia (FTD)	co-ultra PEALut (um-PEA 700 mg + luteolin 70 mg) 1400 mg/day (bid) × 4 weeks	Modulation of GABAergic transmission and cortical oscillatory activity	Improves frontal lobe functions; increases high-frequency oscillations (beta/gamma); restores LICI	Reduces behavioral disturbances; neuroprotective via synaptic modulation
Campolo et al. (28)	Human — Traumatic Brain Injury patients	Traumatic Brain Injury (TBI)	co-ultra PEALut (um-PEA 700 mg + luteolin 70 mg) 1400 mg/day (oral bid) × 180 days	Enhancement of endogenous repair response	Improves memory and cognitive function (MMSE, BNCE scores)	Ameliorates independence and mobility; neuroprotective repair response
Boccella et al. (41)	Animal — SNI mice	Neuropathic pain-related cognitive decline	um-PEA 10 mg/kg ip × 15 days	Restoration of LTP and synaptic maladaptive changes in LEC-DG pathway	Rescues discriminative and spatial memory deficits; restores LTP	Affects 2-AG levels; neuroprotective synaptic restoration
Caltagirone et al. (24)	Human — Ischemic stroke patients	Stroke (ischemic)	co-ultra PEALut (um-PEA 700 mg + luteolin 70 mg) 1400 mg/day (bid sublingual)	Ameliorates neurological status and cognitive impairment	Amelioration of cognitive impairment and memory (MMSE scores)	Improves neurological status; reduces spasticity and pain
Brotini et al. (26)	Human — Parkinson's Disease patients	Parkinson's Disease	um-PEA 1200 mg/day (600 mg bid) × 3 months, then 600 mg/day × 9 months	Add-on to levodopa; modulation of non-motor symptoms	Ameliorates non-motor symptoms of daily living (nM-EDL) including fatigue and anxious-depressive symptoms	Ameliorates motor aspects of daily living (M-EDL); well tolerated
Palma et al. (119)	Human/Animal — ALS patients & Xenopus oocytes	Amyotrophic Lateral Sclerosis (ALS)	um-PEA 1200 mg/day (600 mg bid) × 6 months	Modulation of acetylcholine receptors (AChRs) and neuroinflammation	Reduces desensitization of AChRs-evoked currents; slows respiratory decline	Neuroprotective; improves forced vital capacity (FVC)

[/CODE]

 

Explainer video about PEA: